Provided by Tiger Fintech (Singapore) Pte. Ltd.

uniQure NV

12.76
-0.3900-2.97%
Volume:663.48K
Turnover:8.57M
Market Cap:698.34M
PE:-2.92
High:13.30
Open:13.25
Low:12.73
Close:13.15
Loading ...

Company Profile

Company Name:
uniQure NV
Exchange:
NASDAQ
Establishment Date:
1998
Employees:
209
Office Location:
Paasheuvelweg 25,Amsterdam,Noord-Holland,Netherlands
Zip Code:
1105 BP
Fax:
- -
Introduction:
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Directors

Name
Position
Matthew Kapusta
Chief Executive Officer and Executive Director
David Meek
Non-Executive Director, Chair
Jack Kaye
Non-Executive Director
Jeremy Springhorn
Non-Executive Director
Leonard Post
Non-Executive Director
Madhavan Balachandran
Non-Executive Director
Paula Soteropoulos
Non-Executive Director
Robert Gut
Non-Executive Director

Shareholders

Name
Position
Matthew Kapusta
Chief Executive Officer and Executive Director
Christian Klemt
Chief Financial Officer
Alex Kuta
Executive Vice President, Quality and Regulatory
Ricardo Dolmetsch
President, Research,Development